Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MTLS 
Materialise NV (MTLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: MTLS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.99
1 Year Target Price $8.99
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.67% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 375.86M USD | Price to earnings Ratio 60.3 | 1Y Target Price 8.99 |
Price to earnings Ratio 60.3 | 1Y Target Price 8.99 | ||
Volume (30-day avg) 2 | Beta 1.12 | 52 Weeks Range 3.93 - 9.69 | Updated Date 12/3/2025 |
52 Weeks Range 3.93 - 9.69 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.68% | Operating Margin (TTM) 3.81% |
Management Effectiveness
Return on Assets (TTM) 0.71% | Return on Equity (TTM) 1.77% |
Valuation
Trailing PE 60.3 | Forward PE - | Enterprise Value 285879553 | Price to Sales(TTM) 1.43 |
Enterprise Value 285879553 | Price to Sales(TTM) 1.43 | ||
Enterprise Value to Revenue 0.93 | Enterprise Value to EBITDA 7.67 | Shares Outstanding 59067186 | Shares Floating 24298392 |
Shares Outstanding 59067186 | Shares Floating 24298392 | ||
Percent Insiders 5.3 | Percent Institutions 14.4 |
Upturn AI SWOT
Materialise NV
Company Overview
History and Background
Materialise NV was founded in 1990 in Belgium. It has grown from a small prototyping firm to a global leader in 3D printing solutions and services.
Core Business Areas
- Materialise Medical: Offers medical image processing, surgical planning, and personalized medical devices.
- Materialise Manufacturing: Provides 3D printing services and solutions for various industries, including aerospace, automotive, and consumer goods.
- Materialise Software: Develops software solutions for 3D printing, including data preparation, build management, and process control.
Leadership and Structure
Wilfried Vancraen is the founder and CEO. The company has a board of directors and operates with a matrix organizational structure.
Top Products and Market Share
Key Offerings
- Mimics Innovation Suite: Software for medical image processing and surgical planning. Competitors include Philips, Siemens Healthineers, and GE Healthcare. Specific market share data unavailable.
- Magics: Data preparation and build optimization software for 3D printing. Competitors include Autodesk Netfabb, and 3D Systems 3DXpert. Specific market share data unavailable.
- OnSite: Manufacturing service that provides access to a wide range of 3D printing technologies and materials. Competitors include Proto Labs and Stratasys Direct Manufacturing. Specific market share data unavailable.
Market Dynamics
Industry Overview
The additive manufacturing industry is experiencing rapid growth, driven by advancements in technology, increasing adoption across various sectors, and rising demand for customized products.
Positioning
Materialise NV is a key player in the additive manufacturing industry, known for its comprehensive software solutions, extensive 3D printing services, and strong presence in the medical sector. It has a competitive advantage due to its long history and established reputation.
Total Addressable Market (TAM)
The global 3D printing market is expected to reach hundreds of billion USD by 2030. Materialise NV is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Extensive experience in 3D printing
- Comprehensive product portfolio
- Established presence in the medical sector
- Proprietary software solutions
Weaknesses
- Relatively high price point
- Complexity of some software solutions
- Reliance on third-party hardware
- Dependence on specific industries
- Profitability not consistently high
Opportunities
- Growing demand for customized products
- Expansion into new industries
- Development of new materials and technologies
- Strategic partnerships and acquisitions
- Increasing adoption of 3D printing in healthcare
Threats
- Increasing competition
- Technological advancements by competitors
- Economic downturns
- Regulatory changes
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- DDD
- SSYS
- ONVO
Competitive Landscape
Materialise NV competes with established 3D printing companies. Its advantage lies in its comprehensive software solutions and strong medical presence. Disadvantages include higher price and profitability inconsistencies.
Major Acquisitions
RSPrint Powered by Materialise
- Year: 2019
- Acquisition Price (USD millions): 0
- Strategic Rationale: This wasn't an acquisition but an equity agreement.
Growth Trajectory and Initiatives
Historical Growth: Materialise NV has experienced significant revenue growth over the past decade, driven by the increasing adoption of 3D printing.
Future Projections: Future growth is projected to be strong, driven by expanding applications of 3D printing in healthcare and manufacturing. Analyst estimates vary based on economic conditions and technological advancements.
Recent Initiatives: Recent initiatives include strategic partnerships with medical device companies, expansion of its software portfolio, and investments in new 3D printing technologies.
Summary
Materialise NV is a strong player in the 3D printing industry with a comprehensive product portfolio and a strong presence in the medical sector. However, its high price point and inconsistent profitability are concerns. Future growth depends on its ability to capitalize on growing demand for customized products and expand into new markets.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company-specific factors can change rapidly. Consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Materialise NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-06-25 | CEO - | ||
Sector Technology | Industry Software - Application | Full time employees 488 | Website https://www.materialise.com |
Full time employees 488 | Website https://www.materialise.com | ||
Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers, and printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners; a MES, software providers. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, website, and third-party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis, planning, and engineering, as well as patient-specific design and printing of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, website, and picture archiving and communication system. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to customers serving the automotive, consumer goods industrial goods, semiconductor, art and architecture and aerospace markets. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Smith & Nephew Inc.; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.